Merck, Inc.
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 220
- Registration Number
- NCT06353386
- Locations
- 🇺🇸
UCSD Moores Cancer Center ( Site 0039), La Jolla, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica ( Site 0044), Los Angeles, California, United States
🇺🇸University of Miami Hospital and Clinics, Sylvester Cancer Center-Cancer Research Services ( Site 0051), Miami, Florida, United States
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
- Conditions
- Thrombocythemia, EssentialPrimary MyelofibrosisMyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPolycythemia Vera
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 400
- Registration Number
- NCT06351631
- Locations
- 🇺🇸
DUHS Duke Blood Cancer Center ( Site 6005), Durham, North Carolina, United States
🇺🇸University of Michigan ( Site 6000), Ann Arbor, Michigan, United States
🇺🇸UPMC Hillman Cancer Center ( Site 6004), Pittsburgh, Pennsylvania, United States
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 600
- Registration Number
- NCT06345729
- Locations
- 🇺🇸
CBCC Global Research, Inc. ( Site 0123), Bakersfield, California, United States
🇺🇸Beverly Hills Cancer Center ( Site 0116), Beverly Hills, California, United States
🇺🇸Mount Sinai Cancer Center ( Site 0137), Miami Beach, Florida, United States
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1200
- Registration Number
- NCT06312176
- Locations
- 🇮🇱
Rabin Medical Center ( Site 1453), Petah Tikva, Israel
🇮🇱Sheba Medical Center ( Site 1450), Ramat Gan, Israel
🇮🇹IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 1480), Meldola, Forli-Cesena, Italy
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 780
- Registration Number
- NCT06312137
- Locations
- 🇮🇱
Rambam Health Care Campus-Oncology Division ( Site 2203), Haifa, Israel
🇮🇱Shaare Zedek Medical Center ( Site 2206), Jerusalem, Israel
🇮🇱Rabin Medical Center ( Site 2204), Petah Tikva, Israel
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: H1 Receptor AntagonistDrug: H2 Receptor AntagonistDrug: Steroid Mouthwash (dexamethasone or equivalent)
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 520
- Registration Number
- NCT06305754
- Locations
- 🇨🇳
Hubei Cancer Hospital ( Site 3122), Wuhan, Hubei, China
🇨🇳West China Hospital, Sichuan University ( Site 3126), Cheng Du, Sichuan, China
🇦🇷Centro Privado de RMI Río Cuarto S.A. II ( Site 0310), Río Cuarto, Cordoba, Argentina
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
- Conditions
- Bladder Cancer
- Interventions
- Other: PlaceboBiological: Enfortumab VedotinProcedure: Surgery (RC plus PLND)
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 230
- Registration Number
- NCT06305767
- Locations
- 🇺🇸
UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0104), Los Angeles, California, United States
🇺🇸AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0102), Orlando, Florida, United States
🇺🇸University of Chicago Medical Center ( Site 0109), Chicago, Illinois, United States
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 272
- Registration Number
- NCT06307431
- Locations
- 🇦🇺
Westmead Hospital ( Site 1501), Westmead, New South Wales, Australia
🇺🇸City of Hope Comprehensive Cancer Center-Medical Oncology ( Site 0104), Duarte, California, United States
🇺🇸UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro, Los Angeles, California, United States
A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)
- Conditions
- Malaria
- Interventions
- Other: Plasmodium falciparum
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06294912
- Locations
- 🇦🇺
USC Clinical Trials Brisbane (South Bank) ( Site 0001), South Brisbane, South Australia, Australia
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007).
- Conditions
- Carcinoma, Squamous CellSkin Neoplasms
- Interventions
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1012
- Registration Number
- NCT06295809
- Locations
- 🇮🇱
Sheba Medical Center ( Site 2200), Ramat Gan, Israel
🇳🇴Oslo universitetssykehus, Radiumhospitalet ( Site 2400), Oslo, Norway
🇷🇴Sigmedical Services SRL ( Site 2603), Suceava, Romania